- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
Nasdaq
Wall Street JournalEN
R
RPRX
Royalty Pharma Plc
45.12
0.25+0.55%After Hours: 45.32 +0.20 +0.44%19:42 02/20 EST
OPEN/PREV CLOSE44.88/44.88
TODAY RANGE44.68-45.29
VOL3.47M
MARKET CAP26.03B
52 WEEK RANGE28.97-45.90
AVG VOL (3M)4.06M
% TURNOVER0.60%
TURNOVER--
P/E (TTM)25.33
% RANGE1.37%
EPS(TTM)1.781
P/E(FORWARD)14.55
P/B4.020
BVPS11.22
DIVIDEND0.9400
P/S10.95
BETA--
DIV YIELD2.08%
FREE FLOAT MKT CAP17.50B
SHARES OUTSTANDING576.86M
NEXT EARNINGS05/06-05/11
FREE FLOAT387.93M
LOT SIZE1
EX-DATE02/20/2026
News
Press Releases
Financial Reports
Profile
Seeking Alpha·9h ago
Teva, Medincell granted FDA review for long-acting antipsychotic
Simply Wall St·4d ago
Stronger 2026 Guidance, Buybacks, and Manager Shift Might Change The Case For Investing In Royalty Pharma (RPRX)
Seeking Alpha·5d ago
Royalty Pharma: 2025 Financial Performance And Strategic Outlook
Simply Wall St·02/14 15:38
Royalty Pharma (RPRX) Valuation Check After Strong Portfolio Growth And 2026 Guidance Update
TipRanks·02/14 00:24
Royalty Pharma Earnings Call Balances Strength And Risk
Seeking Alpha·02/13 23:33
Dividend Champion, Contender, And Challenger Highlights: Week Of February 15
Simply Wall St·02/12 20:32
Royalty Pharma (RPRX) Margin Reset To 32.6% Tests Bullish Profitability Narratives
Seeking Alpha·02/12 17:16
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View
TipRanks·02/12 13:38
Royalty Pharma price target raised to $51 from $45 at Goldman Sachs
TipRanks·02/12 13:15
Royalty Pharma price target raised to $61 from $56 at Morgan Stanley
TipRanks·02/12 12:59
Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)
Seeking Alpha·02/11 21:45
Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions
Same Industry
Name/Symbol
Change%
Price